Oral Mucositis Exhibits Significant Growth in Pipeline with Maximum Drug Candidates in Phase II

The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates, of which one drug candidate is in Phase III stage of development, while seven drug candidates are in Phase II stage, four drug candidates are in Phase I stage, five drug candidates are in Pre-Clinical stage and one drug candidate is in the Discovery stage. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis

As per the findings of the research, around 39.0% drug candidates of oral mucositis pipeline are being developed to be administered by topical route, 17.0% are being developed to be administered by oral route, 17.0% are being developed to be administered by intravenous route and 5.0% by subcutaneous route. Route of administration of around 22.0% drug candidates of oral mucositis pipeline is not disclosed.

Many companies are involved in the development of drugs for the oral mucositis therapeutics pipeline, with their products in different phases. Daewoong Pharmaceutical Co., Ltd. has its drug candidates in the Phase III stage of development. Cellceutix Corporation, Onxeo S.A. and Novartis AG have their drug candidates in the Phase II stage of development. Galera Therapeutics, Inc. has two drug candidates each in Phase II and Phase I stage of development. Oragenics, Inc. has one drug candidate in Discovery stage of development.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc., Onxeo S.A., Novartis AG, TFS Corporation, Izun Pharmaceuticals Corp., Oragenics, Inc., Wellstat Therapeutics Corporation, Otsuka Holdings Co., Ltd. and Galera Therapeutics, Inc.